193 related articles for article (PubMed ID: 19154415)
1. Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo.
Devoogdt N; Rasool N; Hoskins E; Simpkins F; Tchabo N; Kohn EC
Cancer Sci; 2009 Mar; 100(3):434-40. PubMed ID: 19154415
[TBL] [Abstract][Full Text] [Related]
2. The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells.
Simpkins FA; Devoogdt NM; Rasool N; Tchabo NE; Alejandro EU; Kamrava MM; Kohn EC
Carcinogenesis; 2008 Mar; 29(3):466-72. PubMed ID: 17916899
[TBL] [Abstract][Full Text] [Related]
3. Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells.
Hoskins E; Rodriguez-Canales J; Hewitt SM; Elmasri W; Han J; Han S; Davidson B; Kohn EC
Gynecol Oncol; 2011 Sep; 122(3):656-62. PubMed ID: 21676452
[TBL] [Abstract][Full Text] [Related]
4. Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cells.
Rasool N; LaRochelle W; Zhong H; Ara G; Cohen J; Kohn EC
Clin Cancer Res; 2010 Jan; 16(2):600-9. PubMed ID: 20068074
[TBL] [Abstract][Full Text] [Related]
5. Mucosal Progranulin expression is induced by H. pylori, but independent of Secretory Leukocyte Protease Inhibitor (SLPI) expression.
Wex T; Kuester D; Schönberg C; Schindele D; Treiber G; Malfertheiner P
BMC Gastroenterol; 2011 May; 11():63. PubMed ID: 21612671
[TBL] [Abstract][Full Text] [Related]
6. Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer.
Zheng D; Gui B; Gray KP; Tinay I; Rafiei S; Huang Q; Sweeney CJ; Kibel AS; Jia L
Oncogene; 2016 Sep; 35(36):4807-15. PubMed ID: 26876202
[TBL] [Abstract][Full Text] [Related]
7. Utility of progranulin and serum leukocyte protease inhibitor as diagnostic and prognostic biomarkers in ovarian cancer.
Carlson AM; Maurer MJ; Goergen KM; Kalli KR; Erskine CL; Behrens MD; Knutson KL; Block MS
Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1730-5. PubMed ID: 23878295
[TBL] [Abstract][Full Text] [Related]
8. microRNA-539 functions as a tumor suppressor in papillary thyroid carcinoma via the transforming growth factor β1/Smads signaling pathway by targeting secretory leukocyte protease inhibitor.
Xu CB; Liu XS; Li JQ; Zhao X; Xin D; Yu D
J Cell Biochem; 2019 Jun; 120(6):10830-10846. PubMed ID: 30706537
[TBL] [Abstract][Full Text] [Related]
9. Secretory leukocyte protease inhibitor is associated with MMP-2 and MMP-9 to promote migration and invasion in SNU638 gastric cancer cells.
Choi BD; Jeong SJ; Wang G; Park JJ; Lim DS; Kim BH; Cho YI; Kim CS; Jeong MJ
Int J Mol Med; 2011 Oct; 28(4):527-34. PubMed ID: 21687932
[TBL] [Abstract][Full Text] [Related]
10. Secretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinoma.
Wen J; Nikitakis NG; Chaisuparat R; Greenwell-Wild T; Gliozzi M; Jin W; Adli A; Moutsopoulos N; Wu T; Warburton G; Wahl SM
Am J Pathol; 2011 Jun; 178(6):2866-78. PubMed ID: 21641406
[TBL] [Abstract][Full Text] [Related]
11. Secretory leukocyte protease inhibitor is a proliferation and survival factor for pancreatic cancer cells.
Zuo J; Zhang C; Ren C; Pang D; Li Y; Xie X; Tang Z; Jiang X
Clin Transl Oncol; 2015 Apr; 17(4):314-21. PubMed ID: 25319722
[TBL] [Abstract][Full Text] [Related]
12. FAP
Sun L; Ke M; Wang X; Yin M; Wei J; Xu L; Tian X; Wang F; Zhang H; Fu S; Zhang C
Mol Carcinog; 2022 Oct; 61(10):910-923. PubMed ID: 35801406
[TBL] [Abstract][Full Text] [Related]
13. Secretory leukocyte protease inhibitor and progranulin as possible regulators of cervical remodeling in pregnancy.
Samejima T; Nagamatsu T; Akiba N; Fujii T; Sayama S; Kawana K; Taguchi A; Kumasawa K; Iriyama T; Osuga Y; Fujii T
J Reprod Immunol; 2021 Feb; 143():103241. PubMed ID: 33157500
[TBL] [Abstract][Full Text] [Related]
14. The expression and clinical significance of secretory leukocyte proteinase inhibitor (SLPI) in mammary carcinoma using bioinformatics analysis.
Xie W; Zhang H; Qin S; Zhang J; Fan X; Yin Y; Liang R; Long H; Yi W; Fu D; Ma C; Lv M; Yu F
Gene; 2019 Dec; 720():144088. PubMed ID: 31476404
[TBL] [Abstract][Full Text] [Related]
15. A lack of secretory leukocyte protease inhibitor (SLPI) causes defects in granulocytic differentiation.
Klimenkova O; Ellerbeck W; Klimiankou M; Ünalan M; Kandabarau S; Gigina A; Hussein K; Zeidler C; Welte K; Skokowa J
Blood; 2014 Feb; 123(8):1239-49. PubMed ID: 24352879
[TBL] [Abstract][Full Text] [Related]
16. The secretory leukocyte protease inhibitor (SLPI) suppresses cancer cell invasion but promotes blood-borne metastasis via an invasion-independent pathway.
Sugino T; Yamaguchi T; Ogura G; Kusakabe T; Goodison S; Homma Y; Suzuki T
J Pathol; 2007 Jun; 212(2):152-60. PubMed ID: 17455170
[TBL] [Abstract][Full Text] [Related]
17. Secretory leukoprotease inhibitor inhibits cell growth through apoptotic pathway on ovarian cancer.
Nakamura K; Takamoto N; Hongo A; Kodama J; Abrzua F; Nasu Y; Kumon H; Hiramatsu Y
Oncol Rep; 2008 May; 19(5):1085-91. PubMed ID: 18425362
[TBL] [Abstract][Full Text] [Related]
18. A secretory leukocyte protease inhibitor variant with improved activity against lung infection.
Camper N; Glasgow AM; Osbourn M; Quinn DJ; Small DM; McLean DT; Lundy FT; Elborn JS; McNally P; Ingram RJ; Weldon S; Taggart CC
Mucosal Immunol; 2016 May; 9(3):669-76. PubMed ID: 26376365
[TBL] [Abstract][Full Text] [Related]
19. Enhancing the developmental competence of the early embryo using secretory leukocyte peptidase inhibitor.
Kim HS; Ha KS; Kwon HC; Lee SJ; Kim CH; Cheon YP
Differentiation; 2016; 92(1-2):24-34. PubMed ID: 26927923
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of a secretory leukocyte protease inhibitor in human gastric cancer.
Cheng WL; Wang CS; Huang YH; Liang Y; Lin PY; Hsueh C; Wu YC; Chen WJ; Yu CJ; Lin SR; Lin KH
Int J Cancer; 2008 Oct; 123(8):1787-96. PubMed ID: 18688858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
